Cargando…

BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer

Long non-coding RNAs (lncRNAs) participate in cancer cell tumorigenesis, cell cycle control, migration, proliferation, apoptosis, metastasis and drug resistance. The BRAF-activated non-coding RNA (BANCR) functions as both an oncogene and a tumor suppressor. Here, we investigated BANCR's role in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Tian, Qu, Ning, Shi, Rong-Liang, Guo, Kai, Ma, Ben, Cao, Yi-Ming, Xiang, Jun, Lu, Zhong-Wu, Zhu, Yong-Xue, Li, Duan-Shu, Ji, Qing-Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352115/ https://www.ncbi.nlm.nih.gov/pubmed/27462868 http://dx.doi.org/10.18632/oncotarget.10825

Ejemplares similares

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Number of tumor foci predicts prognosis in papillary thyroid cancer
por: Qu, Ning, et al.
Publicado: (2014)

Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway
por: Liao, Tian, et al.
Publicado: (2016)

BRAF Testing in Multifocal Papillary Thyroid Carcinoma
por: Kimbrell, Hillary Z., et al.
Publicado: (2015)

LncRNA WT1-AS Downregulates Survivin by Upregulating miR-203 in Papillary Thyroid Carcinoma
por: Le, Fei, et al.
Publicado: (2020)

DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer
por: Ma, Ben, et al.
Publicado: (2016)

lncRNA SNHG3 acts as a novel Tumor Suppressor and regulates Tumor Proliferation and Metastasis via AKT/mTOR/ERK pathway in Papillary Thyroid Carcinoma
por: Duan, Yu, et al.
Publicado: (2020)

Onco-lncRNA HOTAIR and its functional genetic variants in papillary thyroid carcinoma
por: Zhu, Hui, et al.
Publicado: (2016)

Prognostic lncRNA, miRNA, and mRNA Signatures in Papillary Thyroid Carcinoma
por: Wang, Kun, et al.
Publicado: (2020)

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
por: Melck, Adrienne L., et al.
Publicado: (2010)

Construction and investigation of lncRNA-associated ceRNA regulatory network in papillary thyroid cancer
por: Zhao, Yangjing, et al.
Publicado: (2018)

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature
por: You, Xin, et al.
Publicado: (2018)

LncRNA PROX1-AS1 promotes proliferation, invasion, and migration in papillary thyroid carcinoma
por: Shen, Yanyan, et al.
Publicado: (2018)

LncRNA LUCAT1 as a novel prognostic biomarker for patients with papillary thyroid cancer
por: Luzón-Toro, B., et al.
Publicado: (2019)

Curcumin Inhibits Papillary Thyroid Cancer Cell Proliferation by Regulating lncRNA LINC00691
por: Li, Zhihua, et al.
Publicado: (2022)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

Preliminary screening and analysis of metastasis-related lncRNA and co-expressed papillary thyroid carcinoma mRNA
por: Ge, Ming-Hua, et al.
Publicado: (2018)

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
por: Zhang, Peitao, et al.
Publicado: (2022)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients with Acromegaly
por: Kim, Hee Kyung, et al.
Publicado: (2014)

LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer
por: Song, Bin, et al.
Publicado: (2019)

Diagnostic Value of Serum lncRNA HOTAIR Combined with Galectin-3 in Benign and Papillary Thyroid Carcinoma
por: Li, Li, et al.
Publicado: (2021)

Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma
por: Lin, Dao-zhe, et al.
Publicado: (2016)

Estrogen receptor β upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma
por: Li, Mei, et al.
Publicado: (2018)

Genomic Instability-Related LncRNA Signature Predicts the Prognosis and Highlights LINC01614 Is a Tumor Microenvironment-Related Oncogenic lncRNA of Papillary Thyroid Carcinoma
por: Dong, Xubin, et al.
Publicado: (2021)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma
por: Zhou, Changxin, et al.
Publicado: (2019)

Long non-coding (lnc)RNA PAPAS overexpression inhibits tumor growth in papillary thyroid carcinoma by downregulating lncRNA HOTTIP
por: Xiao, Juan, et al.
Publicado: (2020)

Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
por: Issa, Peter P., et al.
Publicado: (2022)

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
por: Yang, Li-Bo, et al.
Publicado: (2015)

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma
por: Henke, Lauren E, et al.
Publicado: (2015)

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates
por: Al-Salam, Suhail, et al.
Publicado: (2020)

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry
por: Estrada-Flórez, Ana P, et al.
Publicado: (2019)

LncRNA BISPR promotes the progression of thyroid papillary carcinoma by regulating miR-21-5p
por: Zhang, Hong, et al.
Publicado: (2018)

Plasma lncRNA GAS8-AS1 as a Potential Biomarker of Papillary Thyroid Carcinoma in Chinese Patients
por: Zhang, Dongxue, et al.
Publicado: (2017)

Construction and analysis of an aberrant lncRNA-miRNA-mRNA network associated with papillary thyroid cancer
por: Jiang, Yanxia, et al.
Publicado: (2020)

Expression of lncRNA-HOTAIR in the serum of patients with lymph node metastasis of papillary thyroid carcinoma and its impact
por: Wu, Lan, et al.
Publicado: (2020)

A cell cycle–related lncRNA signature predicts the progression-free interval in papillary thyroid carcinoma
por: Li, Shuang, et al.
Publicado: (2023)

Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β‐catenin signaling and sensitizes cancer cells to FH535 therapy
por: Wen, Duo, et al.
Publicado: (2018)

Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
por: Zhang, Peitao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k8ep50a3p7l432p1a97rta6s6b